Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$4.64 -6.3%	$4.56	$3.56 ▼ $12.92	$261.85M	0.45	372,381 shs	861,514 shs
MDWD MediWound	$22.00 +3.1%	$17.89	$12.78 ▼ $24.00	$237.78M	0.3	91,147 shs	117,114 shs
SLDB Solid Biosciences	$3.20 -3.0%	$3.12	$2.41 ▼ $10.37	$248.05M	2.32	1.08 million shs	868,844 shs
VRCA Verrica Pharmaceuticals	$0.50 -8.1%	$0.51	$0.38 ▼ $9.36	$46.31M	1.73	583,814 shs	227,009 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	+18.37%	-13.43%	-23.93%	-51.00%
MDWD MediWound	0.00%	+8.00%	+27.54%	+29.34%	+34.89%
SLDB Solid Biosciences	0.00%	+13.88%	-25.75%	-37.50%	-61.26%
VRCA Verrica Pharmaceuticals	0.00%	-18.15%	+6.76%	-21.78%	-94.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	1.6608 of 5 stars	3.6	1.0	0.0	2.2	1.7	0.0
MDWD MediWound	2.1205 of 5 stars	3.5	2.0	0.0	2.8	0.8	0.6
SLDB Solid Biosciences	3.921 of 5 stars	4.6	1.0	0.0	2.9	4.2	1.3
VRCA Verrica Pharmaceuticals	3.8692 of 5 stars	3.1	1.0	4.7	2.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.25	Buy	$30.00	546.55% Upside
MDWD MediWound	3.00	Buy	$31.25	42.05% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	365.63% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	1,497.76% Upside

Current Analyst Ratings Breakdown

Latest VRCA, ATXS, MDWD, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/29/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.33 per share	N/A
MDWD MediWound	$19.21M	12.38	N/A	N/A	$3.43 per share	6.41
SLDB Solid Biosciences	$8.09M	30.66	N/A	N/A	$6.27 per share	0.51
VRCA Verrica Pharmaceuticals	$7.18M	6.45	N/A	N/A	$0.47 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$72.89M	-$1.87	N/A	N/A	N/A	N/A	-43.58%	-29.36%	8/11/2025 (Estimated)
MDWD MediWound	-$6.72M	-$2.09	N/A	N/A	N/A	-142.29%	-82.17%	-33.67%	8/13/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$67M	-$1.20	N/A	N/A	N/A	-625.06%	-591.84%	-141.63%	8/13/2025 (Estimated)

Latest VRCA, ATXS, MDWD, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
3/19/2025	Q4 2024	MDWD MediWound	-$0.59	-$0.36	+$0.23	-$0.36	$5.79 million	$5.84 million
3/11/2025	Q4 2024	ATXS Astria Therapeutics	-$0.45	-$0.44	+$0.01	-$0.44	N/A	N/A
3/11/2025	Q4 2024	VRCA Verrica Pharmaceuticals	-$0.25	-$0.24	+$0.01	-$0.24	$1.30 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	22.38	22.38
MDWD MediWound	N/A	2.11	1.99
SLDB Solid Biosciences	N/A	7.85	7.85
VRCA Verrica Pharmaceuticals	N/A	1.34	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
MDWD MediWound	46.83%
SLDB Solid Biosciences	81.46%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	2.90%
MDWD MediWound	9.20%
SLDB Solid Biosciences	13.63%
VRCA Verrica Pharmaceuticals	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	54.80 million	Optionable
MDWD MediWound	80	10.81 million	9.79 million	Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable
VRCA Verrica Pharmaceuticals	40	92.49 million	26.18 million	Optionable

VRCA, ATXS, MDWD, and SLDB Headlines

Recent News About These Companies

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) PT at $8.00

May 25, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to "Hold"

May 24, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts

May 24, 2025 | marketbeat.com

Research Analysts Offer Predictions for VRCA Q2 Earnings

May 20, 2025 | marketbeat.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 10, 2025 | aaii.com

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

RBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)

April 5, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors

April 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, ATXS, MDWD, and SLDB Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$4.64 -0.31 (-6.26%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.76 +0.12 (+2.59%)

As of 03:59 AM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

MediWound NASDAQ:MDWD

$22.00 +0.66 (+3.09%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$21.96 -0.04 (-0.18%)

As of 04:00 AM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Solid Biosciences NASDAQ:SLDB

$3.20 -0.10 (-3.03%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.21 +0.01 (+0.31%)

As of 03:59 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.50 -0.04 (-8.11%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.50 -0.01 (-1.14%)

As of 04:00 AM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time